Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge ADVISES Hexatronic IN CONNECTION WITH THE ACQUISITION OF Ericsson’s TELECoM CABLES BUSINESS IN Hudiksvall
Mandate

Vinge ADVISES Hexatronic IN CONNECTION WITH THE ACQUISITION OF Ericsson’s TELECoM CABLES BUSINESS IN Hudiksvall

November 04, 2013

Vinge has advised Hexatronic Cable and Interconnect Systems AB, a wholly owned subsidiary of Hexatronic Scandinavia AB (publ), in connection with the acquisition of Ericsson’s fibre and sea cable business in Hudiksvall. In 2013, the business has a pro forma turnover of SEK 350 million and in connection with closing approximately 85 employees will be transferred for fibre production purposes and approximately 30 employees will be transferred during a transitional period for copper cable production purposes.

Vinge’s team consisted of, among others, partner Anders Strid and associates Anna Siesing (M&A and employment), Anna Palmérus (competition) and Ingrid Johansson (commercial property)

ScandCap, through Oskar Säfström, acted as Hexatronic’s financial advisers.

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026